Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian M Aquila

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|April 25, 2020
Positional Analogue Scanning: An Effective Strategy for Multiparameter Optimization in Drug DesignLewis D Pennington, Brian M Aquila, Younggi Choi, et al.
Expert Opinion on Therapeutic Patents|May 19, 2015
Small molecule inhibitor of apoptosis proteins antagonists: a patent reviewAlexander W Hird, Brian M Aquila, Edward J Hennessy, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2012
Discovery of aminopiperidine-based Smac mimetics as IAP antagonistsEdward J Hennessy, Jamal C Saeh, Li Sha, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2014
Structure-based design and synthesis of tricyclic IAP (Inhibitors of Apoptosis Proteins) inhibitorsAlexander W Hird, Brian M Aquila, Michael H Block, et al.
Bioorganic & Medicinal Chemistry Letters|August 13, 2008
Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancerDavid A Scott, Brian M Aquila, Geraldine A Bebernitz, et al.
Journal of Medicinal Chemistry|November 14, 2024
Design and Synthesis of Acyclic Boronic Acid Arginase InhibitorsJason D Shields, Brian M Aquila, David Emmons, et al.
Journal of Medicinal Chemistry|November 22, 2024
Discovery of (2<i>R</i>,4<i>R</i>)-4-((<i>S</i>)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat CancerScott N Mlynarski, Brian M Aquila, Susan Cantin, et al.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582)Edward J Hennessy, Ammar Adam, Brian M Aquila, et al.
Nature Communications|December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemiaAdriana E Tron, Matthew A Belmonte, Ammar Adam, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|April 25, 2020
Positional Analogue Scanning: An Effective Strategy for Multiparameter Optimization in Drug DesignLewis D Pennington, Brian M Aquila, Younggi Choi, et al.
Expert Opinion on Therapeutic Patents|May 19, 2015
Small molecule inhibitor of apoptosis proteins antagonists: a patent reviewAlexander W Hird, Brian M Aquila, Edward J Hennessy, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2012
Discovery of aminopiperidine-based Smac mimetics as IAP antagonistsEdward J Hennessy, Jamal C Saeh, Li Sha, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2014
Structure-based design and synthesis of tricyclic IAP (Inhibitors of Apoptosis Proteins) inhibitorsAlexander W Hird, Brian M Aquila, Michael H Block, et al.
Bioorganic & Medicinal Chemistry Letters|August 13, 2008
Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancerDavid A Scott, Brian M Aquila, Geraldine A Bebernitz, et al.
Journal of Medicinal Chemistry|November 14, 2024
Design and Synthesis of Acyclic Boronic Acid Arginase InhibitorsJason D Shields, Brian M Aquila, David Emmons, et al.
Journal of Medicinal Chemistry|November 22, 2024
Discovery of (2<i>R</i>,4<i>R</i>)-4-((<i>S</i>)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat CancerScott N Mlynarski, Brian M Aquila, Susan Cantin, et al.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582)Edward J Hennessy, Ammar Adam, Brian M Aquila, et al.
Nature Communications|December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemiaAdriana E Tron, Matthew A Belmonte, Ammar Adam, et al.
Pageof 1